Medpace Holdings, Inc.

NASDAQ:MEDP

Medical - Diagnostics & Research

Healthcare
$646.87 -0.98%

-$4.51 today

Market cap
$18.09B
Beta
1.18
P/E (TTM)
28.2
EPS (TTM)
$16.19
52W Low $301.90High $628.92

Volume 0.21M

Average 0.36M

MEDP EBITDA Margin

EBITDA as a percentage of revenue.

Medpace Holdings, Inc.NASDAQ: MEDP

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 24.8%

EBITDA Margin was 24.8% in Q3 FY2026, up 2.1 pp from a year earlier. On a trailing-twelve-month basis it was 22.7%, down 0.6 pp year over year. Over 3 fiscal years it widened by 1.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 23.0% for the fiscal year ending Dec 2026, up from 22.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
24.8%+3.9 pp QoQ
Last fiscal yearDec 2025
22.5%-1.4 pp YoY
LTMSep 2026
22.7%-0.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.1 pp+0.1 pp-2.0 pp
1 year-1.4 pp+0.5 pp+1.9 pp
3 years+1.4 pp+2.1 pp+0.6 pp
5 years+2.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
22.5%
Year-over-year change
-1.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MEDP compares with its peers on the latest reported figures

  • MEDP's LTM Sep 2026 EBITDA Margin of 22.7% is the highest of the 5 companies compared; the peer median is 10.3%.
  • Its year-over-year change of -0.6 pp is the 3rd highest of 5, against a peer median of -1.2 pp.
  • Over three fiscal years its change of +1.4 pp compares with a peer median of -11.1 pp.
MEDP Competitors Peer median
EBITDA Margin for MEDP and competitors
Company Period LTM level YoY 3-year change
MEDPMedpace Holdings, Inc.LTM Sep 202622.7% -0.6 pp+1.4 pp
IQVIQVIA Holdings Inc.LTM Jun 202620.8% -0.6 pp-2.2 pp
ICLRICON Public Limited CompanyLTM Jun 202615.1% -1.9 pp-7.7 pp
CRLCharles River Laboratories International, Inc.LTM Jun 20265.5% -7.6 pp-14.6 pp
FTREFortrea Holdings Inc.LTM Jun 20263.0% +34.4 pp-39.8 pp
Peer median (excluding MEDP) 10.3%-1.2 pp-11.1 pp

Competitors are the stored peer set for MEDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14B1.46B1.89B2.11B2.53B
Cost of Revenue814.22M1.03B1.36B1.45B1.77B
Gross Profit328.16M432.44M524.51M656.31M760.62M
Gross Margin28.7%29.6%27.8%31.1%30.1%
Research & Development00000
Selling, General & Admin108.42M131.4M161.35M180.18M197.56M
Operating Expenses129.54M153.74M187.68M209.44M225.68M
Depreciation & Amortization21.12M22.34M26.33M29.25M28.12M
EBITDA223.08M308.11M362.5M505.17M570.5M
EBITDA Margin19.5%21.1%19.2%24.0%22.5%
Operating Income198.62M278.7M336.83M446.87M534.94M
Operating Margin17.4%19.1%17.9%21.2%21.1%
Interest Income00025M0
Interest Expense105K2.91M488K00
Other Income / Expenses3.24M4.16M(1.14M)29.05M7.44M
Income Before Tax201.85M282.86M335.68M475.92M542.38M
Pre-Tax Margin17.7%19.4%17.8%22.6%21.4%
Income Tax Expense20M37.49M52.87M71.54M91.25M
Net Income181.85M245.37M282.81M404.39M451.12M
Net Margin15.9%16.8%15.0%19.2%17.8%
EPS (Basic)5.067.579.2013.0615.64
EPS (Diluted)4.817.288.8812.6315.28
Weighted Avg Shares35.86M32.39M30.72M30.96M28.85M
Weighted Avg Shares (Diluted)37.7M33.67M31.84M32.01M29.53M

Medpace Holdings, Inc.

NASDAQ:MEDP

Intrinsic Alpha fair value

Locked

Current Price

$646.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.